<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366670/" ref="ordinalpos=4173&amp;ncbi_uid=4053986&amp;link_uid=PMC3366670" image-link="/pmc/articles/PMC3366670/figure/marinedrugs-10-00694-f004/" class="imagepopup">Figure 4.  From: A Marine Anthraquinone SZ-685C Overrides Adriamycin-Resistance in Breast Cancer Cells through Suppressing Akt <span class="highlight" style="background-color:">Signaling</span>. </a></div><br /><div class="p4l_captionBody">Effect of SZ-685C on the Akt signaling pathway in MCF-7/ADR and MCF-7/Akt cells. Cells were treated with different concentrations of ADR (<b>A</b>) and SZ-685C (<b>B</b>) for 48 h as noted. Western blotting analysis was performed using antibodies against phospho-Akt (Ser473 or Thr308), total Akt, phospho-Bad (Ser 136), total Bad, and Bcl-xL, with Actin used as a loading control.</div></div>